On Sat, Mar 26, 2016 at 11:45 PM, jrhorn <jrh...@u.washington.edu> wrote:
> Tim > > > > Not sure why. Not sure what it does. This is difficult to load, but it > looks like it is a DrugBank database. I would avoid using for any clinical > purpose. > > > > What is it? > > > > John > Apologies for being to vague. Why are people doing this DDI work when this great resource is already available? If ou are not familiar with RxNorm, a little bit of observation and reading will explain what it is. > > > *From:* Timothy Cook [mailto:t...@datainsights.tech] > *Sent:* Saturday, March 26, 2016 3:30 PM > *To:* Richard Boyce > *Cc:* public-semweb-lifesci@w3.org; linik...@gmail.com; > brian.leba...@va.gov; bho...@genelex.com; cjvit...@partners.org; > cui....@uth.tmc.edu; mal...@pharmacy.arizona.edu; > daniela.olive...@insight-centre.org; e...@squishymedia.com; > draper.e...@mayo.edu; george.li...@va.gov; gmce...@ashp.org; > jschnei...@pobox.com; har...@pitt.edu; jeffniel...@gmail.com; > sundaram.medimm...@gmail.com; jrh...@u.washington.edu; jkli...@ncpdp.org; > j...@rxdoc.me; jmba...@stanford.edu; ka...@pitt.edu; kim.no...@pfizer.com; > laura.slaugh...@gmail.com; lori.idem...@gmail.com; > pet...@pharmacy.arizona.edu; maria.herr...@kcl.ac.uk; > breitenstein.matt...@mayo.edu; mbrochhau...@uams.edu; > matthias.samw...@meduniwien.ac.at; michel.dumont...@stanford.edu; > michael.mil...@systemsbiology.org; michael.lieb...@ipqanalytics.com; > m...@jackpo.org; na...@worldvista.org; nick.tatone...@columbia.edu; > hassanza...@us.ibm.com; yongq...@med.umich.edu; oliv...@nlm.nih.gov; > be...@dbis.rwth-aachen.de; nyt...@idi.ntnu.no; > ratnesh.sa...@insight-centre.org; freimuth.rob...@mayo.edu; > sam.hab...@gmail.com; scott.nelson...@gmail.com; serkanay...@gmail.com; > vale...@genelex.com; xjing2...@gmail.com > *Subject:* Re: Minutes from the 2/24/16 DDI Information task force > discussion (content sub group) > > > > Why? > > > > https://rxnav.nlm.nih.gov/InteractionAPIs.html# > <https://rxnav.nlm.nih.gov/InteractionAPIs.html> > > > > > > > > On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce <rd...@pitt.edu> wrote: > > (FYI for folks on the public-semweb-lifesci list who are not participating > in the task force [1]) > > Hello, > > Below I have pasted the minutes from the last meeting of the content > sub-team for the DDI Minimum Information Model task force [1]. I apologize > that I was forgot to record the meeting but I have tried to write detailed > minutes. The full set of minutes for the task force are available [2]. > > 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce > 2. https://goo.gl/TKWfNN > > ------------ > Minutes for 2/24/2016 (Content subgroup) > > > > *In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh, > Richard Boyce, Sam Habiel* > > > > Meeting recording: None taken (Rich forgot to start the recording, Sorry!) > > > > Meeting: > > · Brief discussion of progress on the *proposed task force > activities:* > > > > 1. *Clarify definitions *for the seven minimum information items > recommended by prior AHRQ drug interaction conference series > > o A sub-team has been working on creating definitions. Initial ideas > have been developed and will be discussed over the next month: > https://goo.gl/N0MxPd > > o Some questions were raised by the sub-team that were discussed later > during the meeting. > > > > 2. *Propose additional attributes* > > o Depends on Activity 1 > > > > 3. *Create deliverables* using an interesting and non-trivial set of > potential drug-drug interactions: > > o Depends on Activities 1 and 2 > > 4. *Create a foundation for further collaborative work* by > disseminating results through an interest group note, a website, and an > online discussion forum > > o Ratnesh Sahay has created a project that will be used for advancing > development of the interest group note: > https://github.com/W3C-HCLS/w3c-ddi > > i. A very initial outline > can be seen here: http://goo.gl/ZMU1Wm > > ii. All persons who have > participated in the calls have been listed as contributors for now (in > alphabetical order by first name). Please email Rich Boyce with spelling > corrections and the affiliation you would like (or if you would like your > name removed) > > o Scott Nelson submitted a panel proposal on 3/10 to AMIA to discuss > the topic of including seriousness as a minimum information item > > > > · Discussion of what DDI content to include in our deliverables. > > o Sub-team members had made progress on suggesting interacting pairs > based on known issues with DDI evidence and knowledge > > § See https://goo.gl/rYpmjt > > o Rich created a survey to increase the participation: > https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X > > § *Survey closes EOB Wednesday 3/30* > > o It was decided that only one or two PDDIs will be selected for each > category. The group agreed that, for each PDDI, a decision tree will be > created that provides 1) information that can help contextualize the > interaction depending on drug and patient factors, 2) management > recommendations depending on the contextualizing factors in (1), and 3) > evidence supporting or refuting each scientific claim made for (1) > > § Such decision trees have already been created by John Horn and Phil > Hansten for several interactions as part of Dan Malone’s AHRQ grant > (R21HS023826). > > · These can be used for the project as long as we provide > citation to the authors and grant. > > · These interactions might fit as representative for certain > information categories. The group agreed that, for those cases, additional > interactions will be chosen to provide heterogeneity > > · Discussion of stakeholders > > o The question of who the stakeholders are for the min info model came > up from the Standard sub-team. The content sub-team agreed that the > stakeholders included primarily the following: > > § Clinicians (doctors, nurses, pharmacists, and various practitioners) > who must use PDDI information to make clinical decisions > > § Persons who create systems that provide PDDI information to clinicians > in various settings (e.g., database vendors, drug information editorial > boards) > > § Organizations that provide publicly available lists of drug-drug > interactions (e.g., developers of RxNorm) > > o Clarification of this in writing is planned > > · Discussion of use cases: > > o Members of the standard sub-team had suggested using Medication > Reconciliation as a target use case for showing the value of the info model > (e.g., competency questions). Rich asked the content sub-team for comment > > § It was agreed that med rec is an important use case but one that can > probably be broken down into a number of smaller use cases depending on the > phase of the medication therapy process in question (e.g., ordering, > consulting, monitoring) > > o Clarification of this in writing is planned and also a focused > discussion at our “all team” meeting in May. > > · *Action Items* > > § Rich will merge the final results of the survey on suggested PDDIs ( > https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X) into the > google sheet (https://goo.gl/rYpmjt) > > § He will then go through and highlight the PDDIs for which decision > trees have been created as part of Dan Malone’s AHRQ grant > > - The next meeting will finalize the list and future meetings will > finalize decision trees for the chosen interactions. In parallel, the > standard sub-team will work on representing the chosen interactions, > seeking feedback as they go. > > > > -- > > Richard D Boyce, PhD > > Assistant Professor of Biomedical Informatics > > Faculty, Center for Pharmaceutical Policy and Prescribing > > Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and > Training Program > > University of Pittsburgh > > rd...@pitt.edu > > Office: 412-648-9219 > > Twitter: @bhaapgh > > > > > > -- > > Timothy W. Cook, President > > Data Insights, Inc. > -- Timothy W. Cook, President Data Insights, Inc.
